SCHEMBL4240964

SCHEMBL4240964

O=c1nc(-c2ccc3[nH]ncc3c2)cc(-c2ccc(Oc3ccccc3)cc2)[nH]1

nearest known ligand 0.82

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDC7 O00311 12/20 0.82
GSK3B P49841 4/20 0.82
CDK5 Q00535 3/20 0.82
DYRK1A Q13627 3/20 0.82
PIM1 P11309 3/20 0.82
CSNK2A1 P68400 3/20 0.82
CLK2 P49760 2/20 0.82
CLK4 Q9HAZ1 2/20 0.82
MAPK13 O15264 2/20 0.82
DAPK3 O43293 2/20 0.82
ROCK2 O75116 2/20 0.82
CDK1 P06493 2/20 0.82
FGFR1 P11362 2/20 0.82
RPS6KB1 P23443 2/20 0.82
CDK2 P24941 2/20 0.82
MAPK1 P28482 2/20 0.82
CSNK1D P48730 2/20 0.82
GSK3A P49840 2/20 0.82
MAPK12 P53778 2/20 0.82
PRKAA1 Q13131 2/20 0.82

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL385584 0.91 CDC7 (1.00) CDC7GSK3BCDK5DYRK1APIM1
SCHEMBL4243638 0.86 CDC7 (1.00) CDC7GSK3BCDK5DYRK1APIM1
SCHEMBL4237154 0.81 CDC7 (1.00) CDC7GSK3BCDK5DYRK1APIM1
SCHEMBL28247510 0.80 GSK3B (0.76) CDC7GSK3BCDK5DYRK1APIM1
SCHEMBL4245493 0.79 CDC7 (1.00) CDC7GSK3BCDK5DYRK1APIM1
SCHEMBL4243686 0.78 CDC7 (1.00) CDC7GSK3BCDK5DYRK1APIM1
SCHEMBL4241465 0.78 CDC7 (1.00) CDC7GSK3BCDK5DYRK1APIM1
SCHEMBL4245829 0.78 CDC7 (1.00) CDC7GSK3BCDK5DYRK1APIM1
SCHEMBL4246536 0.77 CDC7 (0.67) CDC7GSK3BCDK5DYRK1APIM1
SCHEMBL4239214 0.76 CDC7 (0.60) CDC7GSK3BCDK5DYRK1APIM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2010521-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 Novartis Ag (CH) 2009-01-07 EP claimed
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-12-20 US claimed
WO-2007124288-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS AG (CH) 2007-11-01 WO claimed
EP-2010521-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 Novartis Ag (CH) 2009-01-07 EP disclosed
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-12-20 US disclosed
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-12-20 US disclosed
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) 2007-12-20 US disclosed
WO-2007124288-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS AG (CH) 2007-11-01 WO disclosed
WO-2007124288-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 NOVARTIS AG (CH) 2007-11-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070293491-A1 INDAZOLE COMPOUNDS AND METHODS FOR INHIBITION OF CDC7 CDC7, CDC37, CDC73 CDC7 1/4885GSK3B 1106/4885CDK5 409/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.